You just read:

INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Apr 14, 2019, 20:00 ET